도아고세이 — 덩치도 이익도 기간화학품이 지킨다, 돈을 넣은 곳에서 수익률이 무너졌다Toagosei — commodity chemicals hold up both size and profit; returns collapsed where the money went in東亞合成 — 規模も利益も基幹化学品が支え、資金を投じたところで収益率が崩れた
한 회사 안에 전해(가성소다·염소)와 아크릴 모노머라는 범용 화학, 폴리머·올리고머라는 중간재, 아론알파로 대표되는 접착제와 고기능 재료라는 스페셜티가 같이 있다. EDINET 공시 14년치를 부문별로 이어 붙여 어느 부문이 이익을 내고 어디에 자산이 쌓였는지, 아크릴산 가격이 어디까지 닿는지 가르고(①~⑨), 모든 일본 종목에 같은 틀로 거는 재무 점검(⑩~)으로 손익 엔진·현금·자본 배분·밸류에이션을 잰다. 방향은 단정하지 않는다.One company houses commodity chemicals — electrolysis (caustic soda, chlorine) and acrylic monomers — intermediates in polymers and oligomers, and specialties in adhesives, typified by Aron Alpha, and high-performance materials. Linking 14 years of EDINET filings by segment, we separate which segments earn the profit, where assets have piled up and how far acrylic acid prices reach (①~⑨), then measure the profit engine, cash, capital allocation and valuation with the financial check applied to every Japanese stock in the same frame (⑩~). No view on direction is taken.1つの会社の中に、電解(苛性ソーダ・塩素)とアクリルモノマーという汎用化学、ポリマー・オリゴマーという中間材、 アロンアルフアに代表される接着剤と高機能材料というスペシャリティが同居している。EDINETの開示14年分をセグメント別につなぎ、 どのセグメントが利益を出し、どこに資産が積み上がったか、アクリル酸価格がどこまで効くかを分け(①~⑨)、 すべての日本株に同じ枠組みで掛ける財務点検(⑩~)で損益エンジン・現金・資本配分・バリュエーションを測る。方向は断定しない。
한눈에 — 네 가지 관측At a glance — four observationsひと目で — 4つの観測
아래 절의 숫자를 모은 것Figures collected from the sections below下の節の数字をまとめたもの · Data as of 2026-09-30 · Created 2026-11-01① 10년 넘게 이익은 제자리① Profit has gone nowhere for over 10 years① 10年以上、利益は横ばい
Data as of 2026-09-30 · Created 2026-11-01경상이익은 FY2012 153억엔, FY2025 151억엔이다. 그 사이 매출은 1,482억엔에서 1,623억엔으로 움직였지만 이익의 계단은 생기지 않았다. 영업이익률은 연결 손익계산서가 있는 FY2015 이후로 그린다.Ordinary profit was 153 JPY 100mn in FY2012 and 151 JPY 100mn in FY2025. Revenue moved from 1,482 to 1,623 JPY 100mn in between, but no step-up in profit emerged. Operating margin is plotted from FY2015, when consolidated income statements are available.経常利益はFY2012 153億円、FY2025 151億円だ。 その間に売上高は1,482億円から1,623億円へ動いたが、利益の階段は生まれなかった。 営業利益率は連結損益計算書があるFY2015以降を描く。
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
② 이익은 기간화학품이 낸다② Commodity chemicals generate the profit② 利益を出すのは基幹化学品
Data as of 2026-09-30 · Created 2026-11-01FY2025 부문 이익의 55%가 기간화학품이다(FY2016 29%). 기간화학품은 전해 제품(가성소다·가성칼리·차아염소산소다)·황산·공업용 가스와 아크릴 모노머(아크릴산·에스테르)를 묶은 부문이다 — 말하자면 외형도, 지금의 이익도 범용 화학이 만든다.In FY2025, 55% of segment profit came from commodity chemicals (FY2016 29%). Commodity chemicals bundles electrolysis products (caustic soda, caustic potash, sodium hypochlorite), sulphuric acid, industrial gases and acrylic monomers (acrylic acid, esters) — in other words, both the top line and today’s profit are made by commodity chemicals.FY2025のセグメント利益の55%が基幹化学品だ(FY2016 29%)。 基幹化学品は電解製品(苛性ソーダ・苛性カリ・次亜塩素酸ソーダ)・硫酸・工業用ガスとアクリルモノマー(アクリル酸・エステル)を束ねたセグメントだ — いわば売上規模も今の利益も汎用化学がつくる。
| 부문 (FY2025)Segment (FY2025)セグメント(FY2025) | 매출(억엔)Revenue (JPY 100mn)売上高(億円) | 영업이익(억엔)Operating profit (JPY 100mn)営業利益(億円) | 이익률Margin利益率 | 이익 비중Profit share利益比重 | 자산 수익률Return on assets資産利益率 | 투자 ÷ 감가상각Capex ÷ depreciation投資 ÷ 減価償却費 |
|---|---|---|---|---|---|---|
| 기간화학품Commodity chemicals基幹化学品基幹化学品事業 | 750 | 88 | 11.7% | 55% | 10.7% | 1.93 |
| 폴리머·올리고머Polymers & oligomersポリマー・オリゴマーポリマー・オリゴマー事業 | 377 | 30 | 8.0% | 19% | 5.9% | 4.13 |
| 접착재료Adhesives接着材料接着材料事業 | 137 | 3 | 2.4% | 2% | 1.4% | 4.07 |
| 고기능 재료High-performance materials高機能材料高機能材料事業 | 107 | 12 | 11.0% | 7% | 5.3% | 3.30 |
| 수지가공 제품Plastic processed products樹脂加工製品樹脂加工製品事業 | 290 | 28 | 9.5% | 17% | 6.1% | 0.70 |
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
③ 돈을 넣은 부문에서 수익률이 무너졌다③ Returns collapsed in the segments where money went in③ 資金を投じたセグメントで収益率が崩れた
Data as of 2026-09-30 · Created 2026-11-01부문 자산 수익률(영업이익 ÷ 부문 자산)로 보면, 고기능 재료는 FY 고점 무렵 35.4%에서 FY2025 5.3%로 내려왔다. 같은 기간 고기능·폴리머·접착 부문은 감가상각의 몇 배를 다시 투자해 자산이 커졌는데, 이익은 따라오지 않았다. 반대로 기간화학품은 오랫동안 투자가 감가상각에 못 미쳤다 — 낡은 설비를 돌려 이익을 낸 구조다.Measured by segment return on assets (operating profit ÷ segment assets), high-performance materials fell from 35.4% around its FY peak to 5.3% in FY2025. Over the same period the high-performance, polymer and adhesive segments reinvested several times their depreciation and their assets grew, but profit did not follow. Commodity chemicals, by contrast, invested less than its depreciation for a long time — a structure that earned profit by running old plants.セグメント資産利益率(営業利益 ÷ セグメント資産)で見ると、高機能材料はFYのピーク付近の35.4%からFY2025には5.3%に下がった。 同じ期間、高機能・ポリマー・接着の各セグメントは減価償却費の数倍を再投資して資産が大きくなったが、利益はついてこなかった。 反対に基幹化学品は長い間、投資が減価償却費に届かなかった — 古い設備を回して利益を出した構造だ。
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
④ 접착재료 — 가장 눈에 띄는 몰락④ Adhesives — the most striking decline④ 接着材料 — 最も目立つ凋落
Data as of 2026-09-30 · Created 2026-11-01접착재료 영업이익률은 FY2016 23.5%에서 FY2022 -2.3%까지 떨어졌고 FY2025 2.4%다. 2022년의 구분 변경(개발제품 일부 이관) 이전인 2019년부터 이미 내려가고 있었다. 일본산 아크릴산의 상대가격(프로필렌 대비)과는 계절·추세를 뺀 전년 동기 대비로도 상관이 -0.73이다 — 원료가 압박일 수 있지만, 일본발 수입 물량이 작아 가설로만 둔다.The adhesives operating margin fell from 23.5% in FY2016 to -2.3% in FY2022 and is 2.4% in FY2025. It was already declining from 2019, before the 2022 reclassification (transfer of some development products). Its correlation with the relative price of Japanese acrylic acid (vs propylene) is -0.73 even on a year-on-year basis that strips out seasonality and trend — raw-material costs may be the pressure, but import volumes from Japan are small, so this stays a hypothesis.接着材料の営業利益率はFY2016の23.5%からFY2022の-2.3%まで下がり、FY2025は2.4%だ。 2022年の区分変更(開発製品の一部移管)より前の2019年から、すでに下がっていた。 日本産アクリル酸の相対価格(プロピレン比)とは、季節・トレンドを除いた前年同期比でも相関が-0.73だ — 原料価格が圧迫要因かもしれないが、日本からの輸入数量が小さいため仮説にとどめる。
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
⑤ 아크릴산은 가격으로 닿고, 스프레드로는 안 닿는다⑤ Acrylic acid reaches through price, not through the spread⑤ アクリル酸は価格では効き、スプレッドでは効かない
Data as of 2026-09-30 · Created 2026-11-01기간화학품 분기 마진은 아크릴산 가격과 같이 움직인다 — 전년 동기 대비 변화끼리의 상관 0.54. 원료(프로필렌)를 뺀 스프레드와는 수준 상관이 0.10로 약하고, 스프레드로 만든 함수는 표본 밖에서 직전 4분기 평균보다 낫지 않았다(2.21%p vs 2.13%p). 부문에 나고야 지역 내수용 전해 제품이 함께 들어 있고, 아크릴 단가가 아시아 수출 시세라는 점이 함께 걸린다.The quarterly margin of commodity chemicals moves with the acrylic acid price — correlation of year-on-year changes 0.54. With the spread net of the raw material (propylene), the level correlation is weak at 0.10, and a function built on the spread did no better out of sample than the trailing four-quarter average (2.21pp vs 2.13pp). Two further caveats: the segment also contains electrolysis products for domestic demand in the Nagoya area, and the acrylic unit values are Asian export prices.基幹化学品の四半期マージンはアクリル酸の価格と一緒に動く — 前年同期比の変化同士の相関0.54。 原料(プロピレン)を差し引いたスプレッドとは水準の相関が0.10と弱く、 スプレッドで作った関数は標本外で直前4四半期平均より良くなかった(2.21%pt vs 2.13%pt)。 セグメントに名古屋地区の内需向け電解製品が一緒に入っていること、アクリルの単価がアジアの輸出相場であることも併せて関わる。
| 부문Segmentセグメント | 비교 대상Compared with比較対象 | 수준Level水準 | 분기 차분QoQ difference前期差 | 전년 동기 차분YoY difference前年同期差 | 분기 수Quarters四半期数 |
|---|---|---|---|---|---|
| 기간화학품(전해 + 아크릴 모노머)Commodity chemicals (electrolysis + acrylic monomers)基幹化学品事業 | 아크릴산 가격(한국 수출)Acrylic acid price (Korean exports)アクリル酸価格(韓国輸出) | 0.38 | 0.10 | 0.54 | 34 |
| 기간화학품(전해 + 아크릴 모노머)Commodity chemicals (electrolysis + acrylic monomers)基幹化学品事業 | 아크릴산 스프레드 비율(한국 수출)Acrylic acid spread ratio (Korean exports)アクリル酸スプレッド比率(韓国輸出) | 0.10 | -0.19 | 0.35 | 34 |
| 기간화학품(전해 + 아크릴 모노머)Commodity chemicals (electrolysis + acrylic monomers)基幹化学品事業 | 아크릴산 가격(일본발 수입)Acrylic acid price (imports from Japan)アクリル酸価格(日本からの輸入) | 0.33 | 0.37 | 0.24 | 34 |
| 기간화학품(전해 + 아크릴 모노머)Commodity chemicals (electrolysis + acrylic monomers)基幹化学品事業 | 스프레드 비율(일본발 아크릴산)Spread ratio (acrylic acid from Japan)スプレッド比率(日本発アクリル酸) | 0.01 | 0.15 | -0.32 | 34 |
| 폴리머·올리고머Polymers & oligomersポリマー・オリゴマー事業 | 아크릴산 가격(한국 수출)Acrylic acid price (Korean exports)アクリル酸価格(韓国輸出) | -0.05 | -0.09 | 0.12 | 34 |
| 폴리머·올리고머Polymers & oligomersポリマー・オリゴマー事業 | 아크릴산 스프레드 비율(한국 수출)Acrylic acid spread ratio (Korean exports)アクリル酸スプレッド比率(韓国輸出) | 0.19 | 0.10 | 0.16 | 34 |
| 폴리머·올리고머Polymers & oligomersポリマー・オリゴマー事業 | 아크릴산 가격(일본발 수입)Acrylic acid price (imports from Japan)アクリル酸価格(日本からの輸入) | -0.31 | -0.21 | -0.07 | 34 |
| 폴리머·올리고머Polymers & oligomersポリマー・オリゴマー事業 | 스프레드 비율(일본발 아크릴산)Spread ratio (acrylic acid from Japan)スプレッド比率(日本発アクリル酸) | -0.30 | -0.04 | -0.16 | 34 |
| 접착재료(아론알파 등)Adhesives接着材料事業 | 아크릴산 가격(한국 수출)Acrylic acid price (Korean exports)アクリル酸価格(韓国輸出) | -0.03 | 0.03 | 0.10 | 34 |
| 접착재료(아론알파 등)Adhesives接着材料事業 | 아크릴산 스프레드 비율(한국 수출)Acrylic acid spread ratio (Korean exports)アクリル酸スプレッド比率(韓国輸出) | 0.11 | -0.23 | -0.11 | 34 |
| 접착재료(아론알파 등)Adhesives接着材料事業 | 아크릴산 가격(일본발 수입)Acrylic acid price (imports from Japan)アクリル酸価格(日本からの輸入) | -0.56 | 0.16 | -0.28 | 34 |
| 접착재료(아론알파 등)Adhesives接着材料事業 | 스프레드 비율(일본발 아크릴산)Spread ratio (acrylic acid from Japan)スプレッド比率(日本発アクリル酸) | -0.76 | -0.15 | -0.73 | 34 |
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
⑥ 2012년 日本触媒 폭발 — 일본은 한국 아크릴산을 사 갔다⑥ The 2012 Nippon Shokubai explosion — Japan bought Korean acrylic acid⑥ 2012年の日本触媒の爆発 — 日本は韓国のアクリル酸を買っていった
Data as of 2026-09-30 · Created 2026-11-01日本触媒 姫路 공장 아크릴산 탱크 폭발(2012년 9월 29일) 뒤, 한국의 대일 아크릴산 수출은 월 0.2kt(2012년 7~9월)에서 2.8kt(2012년 10월~2013년 3월)로 늘었다. 아시아 수출 가격은 오르지 않았다 — 일본 국내 수급만 빠듯해졌다는 뜻이다. 도아고세이 연결 경상이익은 FY2012 153억엔, FY2013 153억엔, FY2014 129억엔이었다 (부문 숫자는 EDINET 목록 API 의 10년 창 밖이라 없다).After the acrylic acid tank explosion at Nippon Shokubai’s Himeji plant (29 September 2012), Korea’s acrylic acid exports to Japan rose from 0.2 kt a month (July–September 2012) to 2.8 kt (October 2012–March 2013). Asian export prices did not rise — meaning only Japan’s domestic supply and demand tightened. Toagosei’s consolidated ordinary profit was 153 JPY 100mn in FY2012, 153 JPY 100mn in FY2013 and 129 JPY 100mn in FY2014 (segment figures are unavailable because they fall outside the 10-year window of the EDINET list API).日本触媒姫路製造所のアクリル酸タンク爆発(2012年9月29日)の後、韓国の対日アクリル酸輸出は 月0.2kt(2012年7~9月)から2.8kt(2012年10月~2013年3月)に増えた。 アジアの輸出価格は上がらなかった — 日本国内の需給だけが逼迫したという意味だ。 東亞合成の連結経常利益はFY2012 153億円、FY2013 153億円、FY2014 129億円だった (セグメントの数字はEDINET書類一覧APIの10年の窓の外のため、ない)。
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
⑦ 배당은 세 배, 주가는 장부가 아래⑦ Dividends tripled; the share price sits below book⑦ 配当は3倍、株価は簿価割れ
Data as of 2026-09-30 · Created 2026-11-01주당배당금(현 주식 기준)은 FY2012 20엔에서 FY2025 65엔이 됐고, FY2025 총환원율은 110%다. P/B(가공)는 FY2025 0.82배. 정책보유주식(상장)은 FY2019 이후 줄고 있지만, 연결 순자산 대비 장부가는 FY2025 14.3%로 회사가 밝힌 '10% 정도' 목표보다 높다.Dividend per share (current share basis) went from JPY 20 in FY2012 to JPY 65 in FY2025, and the total payout ratio in FY2025 is 110%. P/B (derived) is 0.82x in FY2025. Cross-shareholdings (listed) have been falling since FY2019, but their book value relative to consolidated net assets is 14.3% in FY2025, above the company’s stated target of ‘around 10%’.1株当たり配当金(現在の株式ベース)はFY2012の20円からFY2025には65円になり、 FY2025の総還元性向は110%だ。P/B(加工値)はFY2025で0.82倍。 政策保有株式(上場)はFY2019以降減っているが、連結純資産に対する簿価はFY2025で14.3%と、会社が示した「10%程度」の目標より高い。
| FY | 상장 정책보유 종목 수Listed cross-shareholdings (number of stocks)上場政策保有銘柄数 | 상장 장부가(억엔)Listed book value (JPY 100mn)上場分の簿価(億円) | 연결 순자산 대비vs consolidated net assets連結純資産比 |
|---|---|---|---|
| 2016 | — | 241 (상장·비상장 합산)241 (listed and unlisted combined)241(上場・非上場の合計) | 13.9% |
| 2017 | — | 322 (상장·비상장 합산)322 (listed and unlisted combined)322(上場・非上場の合計) | 17.2% |
| 2018 | — | 254 (상장·비상장 합산)254 (listed and unlisted combined)254(上場・非上場の合計) | 13.3% |
| 2019 | 75 | 256 | 13.2% |
| 2020 | 70 | 236 | 12.3% |
| 2021 | 52 | 250 | 12.6% |
| 2022 | 45 | 242 | 12.0% |
| 2023 | 38 | 282 | 13.7% |
| 2024 | 37 | 287 | 14.0% |
| 2025 | 34 | 300 | 14.3% |
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
⑧ 투자는 늘었는데 매출·이익으로 이어지지 않는다⑧ Investment rose but did not translate into revenue and profit⑧ 投資は増えたが売上高・利益につながらない
Data as of 2026-09-30 · Created 2026-11-01스페셜티 3부문(접착재료·고기능 재료·폴리머·올리고머)에 FY2016~FY2025 동안 설비투자 717억엔(감가상각 311억엔)이 들어갔고, 전사 연구개발비는 같은 기간 456억엔이다. 연구개발비는 FY2016 37억엔에서 FY2025 67억엔이 됐다. 그 사이 3부문 매출은 472억엔에서 621억엔으로 늘었지만, 영업이익은 92억엔에서 45억엔으로 줄었다 — 9년 중 6년이 전년보다 낮았다. 늘어난 매출이 늘어난 감가상각·비용을 감당하지 못하는 구조가 길게 이어진다. 연구개발비는 부문별로 공시되지 않아 전사 합계를 함께 놓았다. 최근 2년의 대규모 투자는 아직 가동 전일 수 있다.The three specialty segments (adhesives, high-performance materials, polymers & oligomers) received 717 JPY 100mn of capex over FY2016~FY2025 (depreciation 311 JPY 100mn), and company-wide R&D over the same period was 456 JPY 100mn. R&D went from 37 JPY 100mn in FY2016 to 67 JPY 100mn in FY2025. Meanwhile revenue of the three segments grew from 472 to 621 JPY 100mn, but operating profit fell from 92 to 45 JPY 100mn — 6 of 9 years were lower than the year before. A structure in which the extra revenue cannot cover the extra depreciation and costs persists for a long time. R&D is not disclosed by segment, so the company-wide total is shown alongside. Large investments in the last 2 years may not be operating yet.スペシャリティ3セグメント(接着材料・高機能材料・ポリマー・オリゴマー)にFY2016~FY2025の間に設備投資717億円(減価償却費311億円)が投じられ、 全社の研究開発費は同期間に456億円だ。研究開発費はFY2016の37億円からFY2025には67億円になった。 その間に3セグメントの売上高は472億円から621億円に増えたが、営業利益は92億円から45億円に減った — 9年中6年が前年を下回った。増えた売上高が増えた減価償却費・費用を賄えない構造が長く続く。 研究開発費はセグメント別に開示されないため、全社合計を併記した。直近2年の大規模投資はまだ稼働前かもしれない。
| FY | 매출(억엔)Revenue (JPY 100mn)売上高(億円) | 영업이익(억엔)Operating profit (JPY 100mn)営業利益(億円) | 이익률Margin利益率 | 설비투자Capex設備投資 | 감가상각Depreciation減価償却費 | 부문 자산Segment assetsセグメント資産 | 전사 연구개발Company-wide R&D全社研究開発 |
|---|---|---|---|---|---|---|---|
| 2016 | 472 | 92 | 19.6% | 25 | 17 | 400 | 37 |
| 2017 | 498 | 95 | 19.1% | 39 | 18 | 428 | 38 |
| 2018 | 510 | 81 | 15.9% | 53 | 20 | 468 | 37 |
| 2019 | 498 | 70 | 14.0% | 83 | 25 | 542 | 37 |
| 2020 | 474 | 66 | 13.9% | 65 | 29 | 569 | 40 |
| 2021 | 578 | 86 | 14.8% | 49 | 36 | 623 | 44 |
| 2022 | 593 | 64 | 10.7% | 34 | 39 | 669 | 47 |
| 2023 | 582 | 51 | 8.7% | 73 | 40 | 716 | 50 |
| 2024 | 607 | 55 | 9.0% | 121 | 41 | 788 | 58 |
| 2025 | 621 | 45 | 7.3% | 175 | 46 | 959 | 67 |
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
⑨ 기간화학품이 버틴 이유의 절반은 감가상각이 줄어서다⑨ Half the reason commodity chemicals held up is lower depreciation⑨ 基幹化学品が持ちこたえた理由の半分は減価償却費の減少だ
Data as of 2026-09-30 · Created 2026-11-01기간화학품 영업이익률은 FY2016 7.3%에서 FY2025 11.7%로 4.4%p 올랐다. 나누면 감가상각 전 이익률(현금 마진) 개선이 2.0%p, 매출 대비 감가상각 하락이 2.4%p다. FY2016~FY2021 설비투자는 217억엔으로 감가상각 268억엔에도 못 미쳤다 — 설비를 덜 갱신하며 버틴 구간이다. 감가상각은 2022년에 한 번 꺾였다(FY2021 44억엔 → 구분 변경 전 기준 FY2022 35.3억엔, 변경 후 33.3억엔). 그해 설비투자 170억엔으로 자산이 커졌지만 상각은 아직 거의 잡히지 않았다. 감가상각 방법은 FY2016~FY2025 有報 전부 정액법(定額法), 주요 내용연수(건물 2~75년·기계장치 2~17년) 동일 — 회계 변경 문구 없음(원문 확인 2026-10-19). 수선비는 부문별로 공시되지 않아 보수비 절감 여부는 확인할 수 없다.The commodity chemicals operating margin rose 4.4pp, from 7.3% in FY2016 to 11.7% in FY2025. Broken down, the improvement in the pre-depreciation margin (cash margin) is 2.0pp and the fall in depreciation relative to revenue is 2.4pp. Capex over FY2016~FY2021 was 217 JPY 100mn, short even of depreciation of 268 JPY 100mn — a stretch in which it held up by renewing plant less. Depreciation turned down once in 2022 (FY2021 44 JPY 100mn → FY2022 35.3 JPY 100mn on the pre-reclassification basis, 33.3 JPY 100mn after). Capex of 170 JPY 100mn that year enlarged the asset base, but almost none of it shows up in depreciation yet. 감가상각 방법은 FY2016~FY2025 有報 전부 정액법(定額法), 주요 내용연수(건물 2~75년·기계장치 2~17년) 동일 — 회계 변경 문구 없음(원문 확인 2026-10-19). Repair costs are not disclosed by segment, so whether maintenance spending was cut cannot be confirmed.基幹化学品の営業利益率はFY2016の7.3%からFY2025の11.7%へ4.4%pt上がった。 分解すると、減価償却前利益率(キャッシュマージン)の改善が2.0%pt、売上高に対する減価償却費の低下が2.4%ptだ。 FY2016~FY2021の設備投資は217億円で、減価償却費268億円にも届かなかった — 設備の更新を抑えて持ちこたえた区間だ。 減価償却費は2022年に一度下がった(FY2021 44億円 → 区分変更前ベースのFY2022 35.3億円、 変更後33.3億円)。その年の設備投資170億円で資産は大きくなったが、償却はまだほとんど計上されていない。 감가상각 방법은 FY2016~FY2025 有報 전부 정액법(定額法), 주요 내용연수(건물 2~75년·기계장치 2~17년) 동일 — 회계 변경 문구 없음(원문 확인 2026-10-19)。修繕費はセグメント別に開示されないため、保守費の削減の有無は確認できない。
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
⑩ 손익 패널Income statement panel損益パネル — FY2015~FY2025
억엔 · 비율 = 매출 대비 % · FY = 12월 결산 회계연도(1~12월). 第104期 = FY2016 … 第113期 = FY2025, 第114期 = FY2026.JPY 100mn · ratios = % of revenue · FY = 12월 결산 회계연도(1~12월). 第104期 = FY2016 … 第113期 = FY2025, 第114期 = FY2026.億円 · 比率 = 売上高比% · FY = 12월 결산 회계연도(1~12월). 第104期 = FY2016 … 第113期 = FY2025, 第114期 = FY2026. · Data as of 2026-08-07 · Created 2026-11-01| FY | 매출Revenue売上高 | 매출총이익률Gross margin売上総利益率 | 판관비율SG&A ratio販管費率 | 연구개발/매출R&D/revenue研究開発費/売上高 | 영업이익Operating profit営業利益 | 영업이익률Operating margin営業利益率 | 경상이익Ordinary profit経常利益 | 특별손익Extraordinary items特別損益 | 순이익Net profit純利益 | 특별 제외 순이익Net profit ex. extraordinary items特別損益除く純利益 | ROE |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2015 | 1,398 | 25.3% | 16.5% | 2.7% | 123 | 8.8% | 132 | -13 | 67 | 75 | 4.2% |
| 2016 | 1,354 | 29.3% | 17.4% | 2.7% | 161 | 11.9% | 169 | 38 | 138 | 112 | 8.5% |
| 2017 | 1,447 | 29.4% | 17.4% | 2.6% | 175 | 12.1% | 185 | 2 | 129 | 128 | 7.4% |
| 2018 | 1,501 | 28.1% | 17.2% | 2.5% | 164 | 10.9% | 174 | 1 | 127 | 127 | 6.9% |
| 2019 | 1,450 | 28.1% | 18.6% | 2.6% | 138 | 9.5% | 152 | 1 | 104 | 103 | 5.5% |
| 2020 | 1,334 | 28.5% | 19.3% | 3.0% | 123 | 9.3% | 131 | -8 | 81 | 87 | 4.2% |
| 2021 | 1,563 | 29.0% | 17.7% | 2.8% | 177 | 11.3% | 190 | -2 | 138 | 139 | 7.0% |
| 2022 | 1,608 | 26.7% | 17.8% | 2.9% | 144 | 8.9% | 164 | 9 | 125 | 119 | 6.1% |
| 2023 | 1,594 | 26.0% | 18.1% | 3.2% | 125 | 7.8% | 145 | 26 | 122 | 103 | 5.8% |
| 2024 | 1,676 | 27.3% | 18.8% | 3.5% | 142 | 8.5% | 160 | 6 | 119 | 115 | 5.6% |
| 2025 | 1,623 | 29.0% | 20.3% | 4.1% | 142 | 8.7% | 151 | 23 | 128 | 111 | 6.0% |
| 반기Half半期 | 매출Revenue売上高 | 매출총이익률Gross margin売上総利益率 | 판관비SG&A販管費 | 영업이익Operating profit営業利益 | 영업이익률Operating margin営業利益率 | 경상이익Ordinary profit経常利益 | 순이익Net profit純利益 |
|---|---|---|---|---|---|---|---|
| 2024 H2 | 860 | 26.7% | 161 | 69 | 8.0% | 72 | 48 |
| 2025 H1 | 803 | 28.6% | 160 | 70 | 8.7% | 75 | 57 |
| 2025 H2 | 820 | 29.5% | 170 | 72 | 8.7% | 76 | 71 |
| 2026 H1 | 824 | 30.7% | 174 | 79 | 9.6% | 86 | 60 |
⑪ 비용 구조 — 매출 1엔이 어디로 가나Cost structure — where each yen of revenue goesコスト構造 — 売上1円はどこへ行くか
매출 대비 %% of revenue売上高比% · Data as of 2026-08-07 · Created 2026-11-01Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
⑫ 손익 엔진 — 고정비가 얼마나 무거워졌나Profit engine — how much heavier fixed costs have become損益エンジン — 固定費はどれだけ重くなったか
억엔 · % · 계정 분류(勘定科目法)JPY 100mn · % · account-classification method億円 · % · 勘定科目法 · Data as of 2026-08-07 · Created 2026-11-01| FY | 매출Revenue売上高 | 변동비Variable costs変動費 | 고정비Fixed costs固定費 | 공헌이익률Contribution margin限界利益率 | 손익분기 매출Break-even revenue損益分岐点売上高 | 안전마진Margin of safety安全余裕率 | 영업 레버리지Operating leverage営業レバレッジ |
|---|---|---|---|---|---|---|---|
| 2015 | 1,398 | 956 | 319 | 31.7% | 1,009 | 27.9% | 3.59 |
| 2016 | 1,354 | 878 | 315 | 35.2% | 895 | 33.9% | 2.95 |
| 2017 | 1,447 | 942 | 331 | 34.9% | 947 | 34.5% | 2.90 |
| 2018 | 1,501 | 995 | 342 | 33.7% | 1,014 | 32.5% | 3.08 |
| 2019 | 1,450 | 950 | 362 | 34.5% | 1,050 | 27.6% | 3.63 |
| 2020 | 1,334 | 855 | 356 | 35.9% | 990 | 25.8% | 3.88 |
| 2021 | 1,563 | 1,004 | 383 | 35.8% | 1,069 | 31.6% | 3.17 |
| 2022 | 1,608 | 1,074 | 390 | 33.2% | 1,175 | 26.9% | 3.71 |
| 2023 | 1,594 | 1,073 | 395 | 32.6% | 1,211 | 24.0% | 4.16 |
| 2024 | 1,676 | 1,106 | 428 | 34.0% | 1,258 | 25.0% | 4.01 |
| 2025 | 1,623 | 1,035 | 446 | 36.2% | 1,232 | 24.1% | 4.15 |
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
⑬ 발생액 — 순이익 vs 영업현금흐름Accruals — net profit vs operating cash flow発生高 — 純利益 vs 営業キャッシュ・フロー
억엔JPY 100mn億円 · Data as of 2026-08-07 · Created 2026-11-01Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
⑭ CAPEX · FCF — 번 돈과 넣은 돈Capex · FCF — money earned and money investedCAPEX · FCF — 稼いだお金と投じたお金
억엔JPY 100mn億円 · Data as of 2026-08-07 · Created 2026-11-01Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
⑮ 운전자본 — 매출채권 · 재고 · 매입채무 회전Working capital — receivables · inventory · payables turnover運転資本 — 売上債権・棚卸資産・仕入債務の回転
일 · 기말 잔액 기준Days · year-end balances日 · 期末残高ベース · Data as of 2026-08-07 · Created 2026-11-01Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
⑯ ROIC · ROE · ROA — 자본에서 얼마를 버나ROIC · ROE · ROA — how much is earned on capitalROIC・ROE・ROA — 資本からどれだけ稼ぐか
% · Data as of 2026-08-07 · Created 2026-11-01Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
⑰ 자본 배분 — FY2015~FY2025 누적, 돈은 어디로 갔나Capital allocation — cumulative FY2015~FY2025: where did the money go資本配分 — FY2015~FY2025累計、お金はどこへ行ったか
억엔 · 현금흐름표 누계JPY 100mn · cumulative cash-flow statement億円 · キャッシュ・フロー計算書の累計 · Data as of 2026-08-07 · Created 2026-11-01Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
⑱ 특별손익 — 본업 밖 이익이 얼마나 받치나Extraordinary items — how much non-core profit props up earnings特別損益 — 本業以外の利益がどれだけ支えているか
억엔JPY 100mn億円 · Data as of 2026-08-07 · Created 2026-11-01| FY | 특별이익Extraordinary gains特別利益 | 투자주식 매각익Gains on sale of investment securities投資有価証券売却益 | 특별손실Extraordinary losses特別損失 | 감손Impairment減損 | 특별손익 ÷ 세전이익Extraordinary items ÷ pre-tax profit特別損益 ÷ 税引前利益 |
|---|---|---|---|---|---|
| 2015 | 8.3 | 0.4 | 21.7 | 18.3 | -11.3% |
| 2016 | 43.2 | 6.2 | 5.5 | 0.2 | 18.2% |
| 2017 | 8.5 | 4.5 | 6.5 | 2.1 | 1.1% |
| 2018 | 3.3 | 0.0 | 2.5 | — | 0.5% |
| 2019 | 5.7 | 5.5 | 5.1 | 4.1 | 0.4% |
| 2020 | 2.5 | 2.5 | 10.5 | 1.8 | -6.5% |
| 2021 | 18.4 | 17.1 | 20.2 | 10.3 | -1.0% |
| 2022 | 28.4 | 25.5 | 19.7 | 9.6 | 5.0% |
| 2023 | 41.6 | 40.8 | 15.7 | — | 15.2% |
| 2024 | 44.2 | 43.3 | 38.6 | 14.9 | 3.4% |
| 2025 | 53.3 | 52.6 | 30.5 | 4.0 | 13.1% |
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
⑲ 4분기 편중 — 비용을 연말에 몰았나Q4 concentration — were costs bunched at year-end?第4四半期への偏り — 費用を期末に寄せたか
연간 대비 4분기 비중 · 분기 공시 기간 FY2016~FY2023Q4 share of the full year · quarterly-disclosure period FY2016~FY2023通期に対する第4四半期の比重 · 四半期開示期間FY2016~FY2023 · Data as of 2026-08-07 · Created 2026-11-01Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
⑳ 장부 점검 게이지 — 6개 플래그Accounting check gauges — 6 flags帳簿点検ゲージ — 6個のフラグ
빨강 0 · 주황 4 · 최근 연도 기준Red 0 · amber 4 · latest year赤0 · 橙4 · 直近年度ベース · Data as of 2026-08-07 · Created 2026-11-01㉑ 밸류에이션 — P/B · P/E · EV/EBITDAValuation — P/B · P/E · EV/EBITDAバリュエーション — P/B・P/E・EV/EBITDA
배 · 기말 주가는 가공값x · year-end prices are derived values倍 · 期末株価は加工値 · Data as of 2026-08-07 · Created 2026-11-01| FY | 시가총액(억엔)Market cap (JPY 100mn)時価総額(億円) | P/B | P/E | EV/EBITDA | 배당수익률Dividend yield配当利回り | FCF 수익률FCF yieldFCF利回り | 순현금 ÷ 시총Net cash ÷ market capネットキャッシュ ÷ 時価総額 | 투자유가증권 ÷ 시총Investment securities ÷ market cap投資有価証券 ÷ 時価総額 |
|---|---|---|---|---|---|---|---|---|
| 2015 | 1,373 | 0.87 | 20.5 | 4.4 | 2.30% | 13.6% | 32.1% | 19.9% |
| 2016 | 1,518 | 0.90 | 11.0 | 3.8 | 2.25% | 10.3% | 39.9% | 17.8% |
| 2017 | 1,885 | 1.03 | 14.6 | 4.9 | 1.82% | 4.7% | 34.1% | 18.7% |
| 2018 | 1,594 | 0.85 | 12.5 | 3.7 | 2.31% | 5.1% | 41.9% | 17.4% |
| 2019 | 1,672 | 0.86 | 16.1 | 4.4 | 2.36% | 2.0% | 38.9% | 17.2% |
| 2020 | 1,552 | 0.80 | 19.4 | 4.2 | 2.48% | 4.0% | 39.8% | 17.3% |
| 2021 | 1,447 | 0.72 | 10.7 | 2.9 | 3.11% | 6.7% | 44.2% | 19.9% |
| 2022 | 1,350 | 0.66 | 11.0 | 3.6 | 3.23% | -6.9% | 34.1% | 21.1% |
| 2023 | 1,592 | 0.75 | 13.3 | 5.0 | 3.88% | 6.3% | 27.5% | 20.7% |
| 2024 | 1,699 | 0.80 | 14.5 | 5.5 | 3.96% | -1.1% | 17.4% | 20.0% |
| 2025 | 1,758 | 0.82 | 14.0 | 6.4 | 3.97% | -5.2% | 5.5% | 20.5% |
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
㉒ P/E 냐 P/B 냐 — 이 주가는 무엇을 따라가나P/E or P/B — what does this share price track?P/EかP/Bか — この株価は何に連動するか
有報 5년 표 FY2012~FY20255-year tables in the annual securities reports FY2012~FY2025有報の5年表 FY2012~FY2025 · Data as of 2026-08-07 · Created 2026-11-01Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage